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New platinum(II) complexes [PtCl(O,O -acac)(L)] (1)a n d[ P t ( O,O -acac)(γ-acac)(L)] (2)( L= DMSO, a;D M S ,b) containing
a single chelated (O,O -acac) (1), or one chelated and one σ-bonded (γ-acac) acetylacetonate (2) have been synthesized. The
new Pt(II) complexes exhibited high in vitro cytotoxicity on cisplatin sensitive and resistant cell lines and showed negligible
reactivity with nucleobases (Guo and5 -GMP) but selective substitution of DMSO/DMS withsoftbiologicalnucleophiles,such as
L-methionine. In order to assess the ability of the new complexes with respect to cisplatin to induce apoptosis by interaction with
nongenomic targets, the Ames’ test, a standard reverse mutation assay, was carried out on two Salmonella typhimurium strains
(TA98 and TA100). Interestingly, the new complexes did not show the well-known mutagenic activity exhibited by cisplatin and
are, therefore, able to activate apoptotic pathways without interacting with DNA.
1.Introduction
After more than 30 years since its ﬁrst clinical use, cisplatin
is still one of the most widely used drugs in anticancer
chemotherapy [1]. The action mechanism of cisplatin has
been explained in its essential aspects, relatively to its
interaction with DNA.Nevertheless, some essential chemical
processes, related to what happens before the cisplatin
reaches theDNA,generallyconsideredits ﬁnal target,are still
tobeidentiﬁed.Amongtheseprocesses,thebestknownisthe
formation of aquospecies, the main reaction of activation of
thedrug[2,3]which occursinthecytoplasmiccompartment
by hydrolysis of the chloride ligands. However, many other
nongenomicbiomoleculescouldbepotentialtargetsforplat-
inum [4, 5]. Sulfur-rich biomolecules, including free amino
acids(cysteineandmethionine),oligopeptides(glutathione),
and proteins represent good targets for a soft metal such as
Pt [6–9]. Moreover, the need to improve the cisplatin clinical
protocol drives much research into better understanding of
its antitumor activity mechanism [10]. On the other hand,
in order to overcome acquired cellular resistance to cisplatin,
much eﬀort is currently devoted to the discovery of new Pt
anticancer drugs. In the last years several Pt(II) and Pt(IV)
complexeshavebeensynthesised, butonlyafewcompounds,
such as carboplatin and oxaliplatin [1, 11], are actually used
in clinical therapy.
Many studies [12–14], carried out by this research group
[15, 16], aimed to understand not only the nuclear, but
also the cytoplasmic events taking place in cisplatin-treated
cells and able to induce apoptosis. This research group has
long been involved in both the synthesis and preliminary
evaluation of biological activity of the new Pt complexes and
inthesubsequentstudiesofintracellularsignal transduction,
triggered by these molecules and by cisplatin itself [5, 17–
19]. Recently, this group has synthesized and studied new
platinum(II) complexes containing acetylacetonate (acac) in
the metal coordination sphere: [PtCl(O,O -acac)(DMSO)]
(1a) with only one oxygen-bonded chelate acac (O,O -acac),
[Pt(O,O -acac)(γ-acac)(DMSO)] (2a) containing both an
O,O -acac and a σ-bonded acac (γ-acac) and their dimethyl-
sulphide (DMS) analogues (1b and 2b)h a v i n gt h es a m ek e y
structures (Scheme 1),thathaveshown interesting biological2 Metal-Based Drugs
activities [20–23]a n din vitro antimetastatic activity [24].
These compounds not only are able to induce apoptosis in
endometrial cancer cells (HeLa) [21], with activity up to
about 100 times higher than that of cisplatin, but also show
high cytotoxicity in cisplatin-resistant breast cancer cell lines
(MCF-7) [21]. The [Pt(O,O -acac)(γ-acac)(DMS)] complex
(2b) with two acetylacetonate ligands, one O,O -chelate and
the other one sigma-linked by methine in gamma position,
i st h em o r ea c t i v ea m o n gt h et e s t e dc o m p l e x e s[ 22].
As well as their speciﬁc biological activity, these com-
plexesshowed an interesting and selective chemicalreactivity
with nucleophiles with diﬀerent HSAB (Hard-Soft Acid-
Base) character [23]. Indeed, in the complexes [PtCl(O,O -
acac)L] (L = DMSO, DMS), containing two ligands with
diﬀerent hard/soft character on the same metal, selective
substitution reaction in the presence of further ligands was
observed [23] .T h em o r eh a r dl i g a n dr e p l a c e st h eh a r d e r
one, and the more soft replaces the softer one. However, in
these complexes the replacement of Cl− with hard ligands is
kineticallyandthermodynamically lessfavouredwith respect
to the substitution reaction of DMS or DMSO with soft-
type ligands. When only a soft ligand is present, as in the
case of the complexes[Pt(O,O -acac)(γ-acac)L] (L = DMSO,
DMS), the reaction takes place only in the presence of
soft nucleophile, otherwise there is no reaction [23]. These
results, together with the biological studies, indicate that for
these complexes, characterized by low reactivity with hard
nucleophiles and speciﬁc reactivity with soft ligands, the
DNA could not be the main target.
In this context further investigations were carried out in
order to verify this behaviour. We reported the 1HN M R
investigations on reactivity of the new compounds with
hard and soft biological nucleophiles, such as nucleobases
and sulfur amino acids, conﬁrming selective reaction with
the latter [23]. In this work the well-known Salmonella-
his reversion test (Ames’ Test, a standard reverse mutation
assay on the mutagenic capability of the complexes) [25]
on two Salmonella typhimurium strains, TA98 and TA100,
was performed. The bacteria reversed mutation assay (Ames
Test), which is normally used to evaluate the mutagenic
properties of test substrates, can be also used to assess the
ability of tested compounds to interact with DNA [26].
2.MaterialandMethods
2.1. Physical Measurements. 1H NMR spectra were recorded
on a Bruker Avance DPX 400, using CDCl3,a n dD 2Oa s
solvent. 1Ha n d13C chemical shifts in CDCl3 were referred
to TMS, by using the residual protic solvent peaks as internal
references. 1Ha n d13C chemical shifts in D2O were ref-
erenced to TSP (2,2,3,3-d(4)-3-(trimethyl-silyl)-propionic
acid sodium salt), δ(H) = 0ppm, as an external reference.
195Pt chemical shifts were referenced to Na2[PtCl6]( d ( P t )=
0ppm) in D2O as an external reference [27]. Microanalyses
were performed with Carlo Erba Elemental Analyser Mod.
1106 instrument.
2.2. Starting Materials. Commercial reagent grade chemi-
cals, acetylacetone, and solvents were used without further
puriﬁcation. [PtCl2(DMSO)2][ 28]a n dK [ P t C l 3(DMSO)]
[29] were prepared according to previously reported proce-
dures.
2.3. Syntheses of Complexes
2.3.1. [PtCl(O,O -acac)(DMSO)] (1a). A solution of acety-
lacetone (0.097g, 0.973mmol) and KOH (0.027g, 0.487
mmol) in methanol (5mL) was addeddropwise toa solution
of K[PtCl3(DMSO)] (0.204g, 0.487mmol) in water (10mL)
atroomtemperaturewithstirring.Afterfewminutesayellow
precipitateseparatedfromthesolution.Thereactionmixture
was left stirring overnight, and the pale yellow precipitate
of [PtCl(O,O -acac)(DMSO)] (1a) was then isolated by
ﬁltrationanddriedundervacuum(yield0.149g,75%).Anal.
Calcd for C7H13ClO3SPt (407.79): C 20.62, H 3.21; found C
20.73, H 3.28.
Alternatively, asolutioncontainingacetylacetone(0.097g,
0.966mmol) and KOH (0.027g, 0.483mmol) in water
(5mL) was added dropwise to a suspension of cis-
[PtCl2(DMSO)2] (0.204g, 0.483mmol) in water (10mL) at
room temperature with stirring. The reaction mixture slowly
becameayellowsolution.After3h,apaleyellowsolidstarted
to precipitate. The suspension was left under stirring for one
d a y ,a n dt h es o l i dw a st h e nﬁ l t e r e da n dd r i e du n d e rv a c u u m
(yield 0.027g, 26%).
1H NMR in CDCl3 (298K): δ 2.06s [3H, CH3(O,O -
acac)], 2.02s [3H, CH3(O,O -acac)], 5.56s [1H, CH(O,O -
acac)], 3.44s [6H, CH3(DMSO), 3JH-Pt 40Hz].
13C NMR in CDCl3 (298K): δ 26.3 [2C, CH3(O,O -
acac)], 102.3 [1C, CH(O,O -acac)], 185.1 and 185.9 [2C,
CO(O,O -acac)], 44.3 [2C, CH3(DMSO)].
195Pt NMR in CDCl3 (298K): δ −2399.
2.3.2. [Pt(O,O -acac)(γ-acac)(DMSO)] (2a). As o l u t i o no f
acetylacetone (0.358g, 3.576mmol) and KOH (0.114g,
2.860mmol) in methanol (5mL) was added dropwise to a
suspension of cis-[PtCl2(DMSO)2] (0.302g, 0.715mmol) in
methanol (20mL) at room temperature with stirring. The
reaction mixture slowly became a pale yellow solution. After
one day, the solvent was evaporated under vacuum, and the
yellow residue was extracted with CHCl3 (10mL). The chlo-
roformsolutionwasthenﬁlteredtoremoveKClandK(acac),
pentane (30mL) was added, and the resultant solution was
k e p to v e r n i g h ta t5 ◦C. Quadrangular pale yellow crystals of
[Pt(O,O -acac)(γ-acac)(DMSO)] (2a) which separated out
from the solution were ﬁltered, washed with pentane, and
dried under vacuum (yield 0.168g, 50%). Anal. Calcd for
C12H20O5SPt (471.441): C 30.57, H 4.28; found C 30.73, H
4.34.
1HNMR in CDCl3 (298K): δ 2.00s [3H, CH3(O,O -
acac)], 1.95s [3H, CH3(O,O -acac)], 5.53s [1H, CH(O,O -
acac)], 2.29s [6H, CH3(γ-acac)], 4.79s [1H, CH(γ-acac),
2JH-Pt 120Hz], 3.31s [6H, CH3(DMSO), 3JH-Pt 19Hz].
13C NMR in CDCl3 (298K): δ 27.50 and 27.3 [2C,
CH3(O,O -acac)], 102.2 [1C, CH(O,O -acac)], 185.8 and
184.9 [2C, CO(O,O -acac)], 30.9 [2C, CH3(γ-acac)], 42.0
[1C, CH (γ-acac)], 208.5 [2C, CO(γ-acac)], 42.9 [2C,
CH3(DMSO)].
195Pt NMR in CDCl3 (298K): δ −3198.Metal-Based Drugs 3
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Scheme 1: Chemical structure of O,O -chelated acac complexes: 1aand 2a,L= DMSO; 1band 2b,L= DMS.
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2.3.3. [PtCl(O,O -acac)(DMS)] (1b)a n d[ P t ( O , O  -acac)(γ-
acac)(DMS)] (2b). To a chloroform (3mL) solution of 1a
or 2a (0.1g, 0.24mmol for 1a and 0.1g, 0.21mmol for 2a)
a large DMS excess (0.224g, 3.6mmol for 1a and 0.263g,
4.24mmol for 2a) was added. The reaction mixture was left
understirring at room temperature, overnight. The resulting
yellow solution was added to pentane (10mL) and kept
at 5◦C for one day up to the formation of yellow needles
crystals for 1b and pale yellow crystals for 2b. Finally, the
crystals were isolated, washed with pentane, and dried under
vacuum.(Yield0.075g,0.191mmol, 80%for1b.Anal.Calcd
for C7H13ClO2PtS (391.773): C 21.46; H 3.34; found: C
21.27; H 3.20; yield 0.078g, 0.171mmol, 82% for 2b.A n a l .
Calcd for C7H13ClO2PtS (455.428): C 31.65; H 4.43; found:
C 31.72; H 4.56).
1H NMR in CDCl3 of 1b (298K): δ 1.97s [3H,
CH3(O,O -acac)], 1.88s [3H, CH3(O,O -acac)], 5.48s [1H,
CH(O,O -acac)], 2.33s [6H, CH3(DMS), 3JH-Pt 48Hz].
1HNMR in CDCl3 of 2b (298K): δ 1.89s [3H, CH3(O,O -
acac)], 1.95s [3H, CH3(O,O -acac)], 5.47s [1H, CH(O,O -
acac)], 2.20s [6H, CH3(γ-acac)], 4.88s [1H, CH(γ-acac),
2JH-Pt 124Hz], 2.29s [6H, CH3(DMS), 3JH-Pt 51Hz].
13C NMR in CDCl3 of 1b (298K): δ 26.1 and 26.5 [2C,
CH3(O,O -acac)], 101.7 [1C, CH(O,O -acac)], 184.9 and
182.9 [2C, CO(O,O -acac)], 22.1 [2C, CH3(DMS)].
13C NMR in CDCl3 of 2b (298K): δ 27.50 and 27.1
[2C, CH3(O,O -acac)], 101.6 [1C, CH(O,O -acac)], 183.7
and 184.7 [2C, CO(O,O -acac)], 30.9 [2C, CH3(γ-acac)],
40.5 [1C, CH (γ-acac)], 207.2 [2C, CO(γ-acac)], 22.1 [2C,
CH3(DMS)].
195Pt NMR in CDCl3 of 1b(298K): δ −2096. 195Pt NMR
in CDCl3 of 2b (298K): δ −2905.
2.4. Reaction of [PtCl(O,O -acac)(DMSO)], [Pt(O,O -
acac)(γ-acac)(DMSO)], and [Pt(O,O -acac)(γ-acac)(DMS)]
with Guanosine (Guo), 5 -GMP, and L-Methionine. A
solution containing the platinum complex (approximately
2 × 10−3 mmol) and an excess of Guo, 5 -GMP, or L-
methionine (1.6 × 10
−2 mmol) dissolved in D2O( 1m L )w a s
placed in an NMR tube and the reaction monitored by 1H
NMR spectroscopy. For all complexes tested, the reaction
with Guo and 5 -GMP was negligible after 24h, whereas
the L-methionine instantly reacted with the initial Pt
complexes.4 Metal-Based Drugs
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Rapid reaction with L-methionine (decreasing coordinated (#) and increasing free DMS (∗) signals) and negligible or very slow reaction
with 5 -GMP were observed.
2.5. Mutagenic Test (Ames’ Test). Two strains of Salmonella
typhimurium, TA98 and TA100 (kindly supplied by Depart-
ment of Experimental Studies and Applied Medicine,
Hygiene Section, University of Brescia), histidine auxotroph
mutants, deﬁcient in the synthesis of histidine (his−), amino
acid necessary for bacterial growth were used according with
t h em e t h o dp r o p o s e db yA m e se ta l .[ 25]. These strains
contain other mutations that greatly increase the ability to
detect mutagens [30]: the mutation “rfa” causes partial loss
of the lipopolysaccharide barrier coating the surface of the
bacteria and increases permeability to large molecules such
as benzo[a]pyrene that do not penetrate the normal cell
wall; the mutation “uvrB” is a deletion of a gene coding for
DNA excision repair system, resulting in a high sensitivity to
UV rays; the “R-factor” plasmid, pKM101, carries ampicillin
resistance gene. The histidine auxotrophs will only grow
in a medium containing suﬃcient histidine supplement.
To revert to histidine production (prototrophy), or become
his+, a reverse mutation must occur in the original his−
mutation site (found in one of the genes involving histidine
biosynthesis).
Each sample was investigated with the plate incor-
poration test: 100μL/mL of complexes (1a, 2a,a n d2b),
at diﬀerent dilutions with DMSO (from 0.01μg/plate to
30μg/plate), were added to 2mL top agar and to 100μlo f
culture of S. typhimurium growth at optimal concentrations
(108 u.f.c/mL). The mix was poured onto a minimal agar
plate [30, 31]. Three plates were incubated for each of
the dilutions tested. A solvent control (DMSO) was per-
formed. Furthermore, a positive control was carried outMetal-Based Drugs 5
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Figure 2: 1HN M Rs p e c t r ai nD 2O (400.13MHz, standard TSP) of 2b with excess of L-methionine and 5 -GMP at diﬀerent reaction times.
Rapid reaction with L-methionine (decreasing coordinated (#) and increasing free DMS (∗) signals) and negligible or very slow reaction
with 5 -GMP were observed.
using cisplatin, known as compound at strong mutagenic
activity [32, 33], testing the same dilutions of new com-
pounds. The results were expressed as numbers of net
revertants, calculated as diﬀerence between the number of
revertants/plate of tested compounds and the number of
spontaneous revertants enumerated on the control plates.
Moreover, we calculated the mutagenicity ratio (MR)—the
ratio of the number of Salmonella typhimurium revertants
growninthepresenceofthetestedcomplextothenumberof
spontaneously appeared revertants (onthe negative control).
The sample was considered mutagenic when MR ≥ 2.
3.Resultsand Discussion
3.1. Synthesis of Platinum Complexes. The synthesis of
[PtCl(O,O -acac)(DMSO)] (1a), containing a single chelate
acac, was straightforward. Due to its low solubility in the
reactionmedium,itprecipitatesasapaleyellowpowderfrom
the reaction mixture of K[PtCl3(DMSO)] with acetylacetone
and KOH in water. Complex 2awas obtained by treating cis-
[PtCl2(DMSO)2] withacetylacetone and KOHin MeOHand
was isolated from their respective reaction mixtures by an
appropriate workup procedure reported in the experimental
section (Scheme 2).
In both cases, in order to prevent metal reduction, a
slight excess of acetylacetone was used with respect to the
calculated stoichiometric amount of KOH based on starting
platinum complex. It should be noted that the use of the
scarcely soluble cis-[PtCl2(DMSO)2] as a starting platinum
complex for the preparation of 1a in MeOH or water
gave unsatisfactory results. Due to the low solubility of cis-
[PtCl2(DMSO)2], the reaction with acetylacetone and KOH
in MeOH resulted in an excess of acac in solution, even
when using a stoichiometric or substoichiometric amount
of acac and always gave a mixture of 1a, 2a and unreacted
starting material. On the other hand, the reaction of cis-
[PtCl2(DMSO)2] with acetylacetone and KOH in water, in
which both the starting platinum complex and [PtCl(O,O -
acac)(DMSO)] are sparingly soluble, gave analytically pure
1a although a longer reaction time was required and a
lower yield was obtained. In the presence of dimethylsul-
ﬁde (DMS), [PtCl(O,O -acac)(DMSO)] (1a)a n d[ P t ( O,O -
acac)(γ-acac)(DMSO)] (2a) complexes selectively undergo
substitution of the sulfur ligand to give the analogous DMS
complexes [PtCl(O,O -acac)(DMS)] (1b)a n d[ P t ( O,O -
acac)(γ-acac)(DMS)] (2b). Interestingly, the substitution
reaction appears to be very selective not only for 1a,w h e r e
DMSO is the only expected exchangeable ligand, but also6 Metal-Based Drugs
μg/plate
μg/plate μg/plate μg/plate
μg/plate μg/plate
N
e
t
r
e
v
e
r
t
a
n
t
s
/
p
l
a
t
e
N
e
t
r
e
v
e
r
t
a
n
t
s
/
p
l
a
t
e
N
e
t
r
e
v
e
r
t
a
n
t
s
/
p
l
a
t
e
N
e
t
r
e
v
e
r
t
a
n
t
s
/
p
l
a
t
e
N
e
t
r
e
v
e
r
t
a
n
t
s
/
p
l
a
t
e
N
e
t
r
e
v
e
r
t
a
n
t
s
/
p
l
a
t
e
Cisplatin
[PtCl(O,O -acac)(DMSO)], 1a
[PtCl(O,O -acac)(γ-acac)(DMSO)], 2a
[PtCl(O,O -acac)(γ-acac)(DMS)], 2b
1a 2a 2b
0 5 10 15 20 25 30
0
200
400
600
800
1000
1200
1400
0 5 10 15 20 25 30
0 5 10 15 20 25 30
0
200
400
600
800
1000
1200
1400
0
200
400
600
800
1000
O
O
O
O
O
O Me
Me
Me
Me
Me
Me
Pt
Pt
Cl
CH
H
H
TA 98
TA 100
0 5 10 15 20 25 30
0
200
400
600
800
1000
1200
1400
0 5 10 15 20 25 30 0 5 10 15 20 25 30
0
200
400
600
800
1000
0
200
400
600
800
1000
Cisplatin
Pt
Cl Cl
DMSO DMSO O
O
O
O
Me
Me
Me
Me
Pt
CH
H
DMS
H3N NH3
Figure 3: Mutagenicities of 1a, 2a, 2b complexes and cisplatin on TA98 and TA100 Salmonella typhimurium strains.
for 2a, where, in principle, the chloroligand was also able
to undergo substitution with DMS. Therefore, the synthetic
proceduresof 1b-2bcomplexes reported in the experimental
section were developed, taking advantage of the selective
reactivity showed by 1a-2a compounds towards soft ligand
such as DMS. For the synthesis of 1b and 2b complexes, an
excess of DMS was added to 1a and 2a, in order to complete
the substitution reaction (Scheme 3).
3.2. Reactivity Studies. By 1H NMR the reactivity of water
soluble complexes (1a, 2a,a n d2b) with biological nucle-
ophiles (nucleobases and amino acids) was investigated.
The poor water solubility of [PtCl(O,O -acac)(DMS)] (1b)
prevented further investigation on its reactivity and bio-
logical activities. The reactions with soft biological nucle-
ophiles,suchas L-methionine (L-met),rapidlygavethesame
selective substitution of DMSO or DMS, already seen for
these complexes towards classical soft nucleophiles (DMS,
PPh3, ethylene, carbon monoxide) [23]. Indeed, also in the
presence of L-methionine excess both 1a and 2a complexes
gave selective substitution reaction of DMSO aﬀording,
r e s p e c t i v e l y ,t ot h en e u t r a ls p e c i e s[ P t C l ( O,O -acac)(L-met)]
[Pt(O,O -acac)(γ-acac)(L-met)]. Moreover, thissubstitution
reaction not only was more selective but also was faster. In
Figure 1 the 1HNMRtime monitoring ofreaction of 1awith
L-met was reported. Adding L-met excess to a solution of 1a
in D2O, after only 5 minutes (the time needed to record a
1H NMR spectra) the substitution of DMSO ligand and the
coordination of L-Met were observed by the decreasing of
the signal at 3.44ppm, assigned to the coordinated DMSO
ligand.Metal-Based Drugs 7
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At thesame time, the increasing ofthe singlet at2.6 ppm,
attributed to the free DMSO ligand, and the appearance
of new signals related to the O,O -acac carrier ligand were
detected. After 10 minutes, almost the entire starting com-
plex was reacted with the L-met. The substitution reaction
of 1a and 2a with soft biological nucleophiles (L-met) was
more selective, especially in the case of 1a, where another
goodleavinggroupsuch asCl− ispresentinthecoordination
sphere. Contrary, in the reactions with biological nitrogen
ligands, such as purines (Guo, 5 -GMP), both 1a and 2a
showed little reactivity even after several hours. In the 1H
NMR spectra in D2Oo f1a i nt h ep r e s e n c eo f5  -GMP
(Figure 1) no new signals of coordinated or free DMSO
ligand assignable to substitution reaction products were
observed. The same selective reactivity in the substitution
of the soft sulfur ligand was observed in the reaction of the
water soluble [Pt(O,O -acac)(γ-acac)(DMS)] (2b)w i t hL -
methionine, Guo, and 5 -GMP. Also in this case a very fast
substitution reaction was noted in the presence of L-met
excess. InFigure 2the 1HNMRspectraofreactionof 2bwith
L-met were reported.
By addition of L-met excess to a deuterated water solu-
tion of 2b, the decreasing of singlet at 2.29ppm, attributed
to coordinated DMS ligand, and the increasing of new
signal of O,O -acac and γ-acac, assigned to the [Pt(O,O -
acac)(γ-acac)(L-met)] species, were identiﬁed after only 10
minutes. Analogously to 1a and 2a complexes, in the 1H
NMR time monitoring of the reaction of 2b with Guo
or 5 -GMP (Figure 2) any substitution reaction occurred.
Such behaviour is very peculiar and suggests a possible
selectivity in the substitution reaction at the metal centre
in these systems ruled by the hard-soft characteristics of
the leaving and incoming ligands. This selectivity could be
also operating when the substitution at the metal involves
biological sulfur ligands such as thiols or thioethers attached
to proteins.
3.3. Mutagenic Activity. These complexes have exhibited
interesting biological activities [21–23]. Furthermore, these
compounds not only induced apoptosis in endometrial
cancer cells (HeLa), but also showed high cytotoxicity in
cisplatin-resistant breast cancer cell lines, with activity up
to about 100 times higher with respect to cisplatin and
in vitro antimetastatic activity [24]. Among all complexes,
[Pt(O,O -acac)(γ-acac)(DMS)] (2b)w a sf o u n dt ob et h e
most active. Diﬀerently from cisplatin, for which the activity
appears to be associated to both cellular accumulation and
DNA linking, intracellular total platinum amount analysis
indicated a scarce reactivity of new complexes with DNA,
the principal biological target of cisplatin [21, 22]. Moreover
recent in vivo studies aimed to evaluate the outcomes
of perinatal treatment with chemotherapeutic agents on
key CNS developmental processes such as neural cells
proliferation, migration, and diﬀerentiation demonstrated
that the brain platinum content after [Pt(O,O -acac)(γ-
acac)(DMS)] treatment was notably higher (approximately
4-fold as much) than after cisplatin.H o w e v e r ,c o m p a r e d
with cisplatin,[ P t ( O,O -acac)(γ-acac)(DMS)] induces less
severe changes on fundamental events of neuroarchitecture
development [24]. All these data suggested that the cytotoxi-
city mechanisms of the new complexes may not necessarily
require interaction with DNA and that their cytotoxicity
is associated only with the intracellular accumulation. The
Ames’ test, carried out on the new complexes, conﬁrmed
these results.
The mutagenic activities of new complexes (1a, 2a,a n d
2b) with respect to cisplatin on two Salmonella typhimurium
strains (TA98 and TA100) were reported in Figure 3 and
Table 1. As expected a rising of revertants at increasing doses
of cisplatin was observed, reaching the highest number of
net revertants at the highest tested doses (30μg/plate) on
both strains. Interestingly, at the same tested doses and on
both Salmonella typhimurium strains the new complexes
showed negligible mutagenic activity. Indeed, also at the
highesttesteddosesnonetrevertantscolonieswereobserved,
whereas only cisplatin exhibited the well-known [32, 33]
dose-dependent increase in revertants. Moreover, for each
complex the MR was always below 2.
Hence, we can assert that the biological activity of the
new Pt(II) acac complexes is related to the reaction with
nongenomic biological targets.
4.Conclusions
We have reported new Pt(II) β-diketonate complexes with
an intriguing chemical reactivity and interesting biological
activities. The new complexes coordinate, instead of the
mono- and bidentate amine ligands of the classical cisplatin
analogues, O,O -acetylacetonate (acac) chelate as carrier
ligand and DMS or DMSO ligands. Due to their ability to
induce apoptosis in endometrial cancer cells (HeLa) and
in cisplatin-resistant breast cancer cell lines (MCF-7) with
diﬀerentpathwayswithrespecttocisplatin,furtherinvestiga-
tions were performed on the reactivity of novel compounds
with biological targets and on the mutagenic capability.
Indeed, diﬀerently from cisplatin, for which the activity
appears to be associated with its intracellular accumulation
and formation of DNA adducts, the cytotoxicity of the new
compound is only related to the intracellular accumulation.
These complexes,besidestheirspeciﬁcbiologicalactivity,
showed an interesting and selective chemical reactivity
towards nucleophile with diﬀerent HSAB (Hard-Soft Acid-
Base) character. The same selective reactivity has been
studied towards biological nucleophiles, such as nucleobase
and amino acids. The new complexes showed also in these
cases negligible reactivity with nucleobases (Guo and 5 -
GMP) and gave selective substitution of DMSO or DMS
with soft biological nucleophiles, such as L-methionine,
suggesting that the cellular targets could be amino acid
r e s i d u e si np r o t e i n sa n de n z y m e si n v o l v e di nt h ea p o p t o t i c
induction.
Interestingly, in the mutagenic tests carried out in this
work on two Salmonella typhimurium strains (TA98 and
TA100) the new complexes showed, also at the highest
tested doses, insigniﬁcant mutagenic activity with respect to
cisplatin, known for its strong mutagenic activity and then
used as a positive control. All these data suggest that the
cytotoxicity mechanisms of the new β-diketonate complexesMetal-Based Drugs 9
may not necessarily require interaction with DNA and that
their biological activity is connected to the reaction with
nongenomic biological targets.
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